A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor‐alpha
Olivry, T., Dunston, S. M., Rivierre, C., Jackson, H. A., Murphy, K. M., Peters, E., & Dean, G. A. (2003, February 1). Veterinary Dermatology, Vol. 14, pp. 37–46.
author keywords: allergy; atopic dermatitis; atopy; canine; misoprostol; randomized controlled trial; tumour necrosis factor alpha
MeSH headings : Administration, Oral; Animals; Dermatitis, Atopic / drug therapy; Dermatitis, Atopic / veterinary; Dermatologic Agents / administration & dosage; Dermatologic Agents / pharmacology; Dermatologic Agents / therapeutic use; Dog Diseases / drug therapy; Dog Diseases / pathology; Dogs; Double-Blind Method; Female; Fluorescent Antibody Technique, Indirect / veterinary; Male; Misoprostol / administration & dosage; Misoprostol / pharmacology; Misoprostol / therapeutic use; RNA, Messenger / drug effects; RNA, Messenger / metabolism; Treatment Outcome; Tumor Necrosis Factor-alpha / drug effects; Tumor Necrosis Factor-alpha / metabolism
topics (OpenAlex): Dermatology and Skin Diseases; Asthma and respiratory diseases; Allergic Rhinitis and Sensitization
TL;DR:
The modest efficacy of misoprostol for treatment of canine AD is confirmed and its mild anti-allergic effects are suggested to be associated with either inhibition of inflammatory cell emigration or TNFalpha production.
(via
Semantic Scholar)
UN Sustainable Development Goal Categories
Sources: Web Of Science, ORCID, NC State University Libraries